HAROON SIDDIQUE: Open Payments
NPI 1457461519 · DECATUR, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,843 in 185 payments from 13 companies in 2025. Trend: 2023 $1,991 · 2024 $2,020 · 2025 $2,843
Food & beverage: $2,843
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 51 | $734 |
| Neurocrine BioSciences, Inc. | 13 | $416 |
| ABBVIE INC. | 22 | $366 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $324 |
| Janssen Pharmaceuticals, Inc | 9 | $223 |
| Teva Pharmaceuticals USA, Inc. | 19 | $204 |
| Otsuka America Pharmaceutical, Inc. | 13 | $189 |
| Supernus Pharmaceuticals, Inc. | 23 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Luye Pharma (USA) Ltd. | 2 | $56 |
Products named: COBENFY, INGREZZA, VRAYLAR, CAPLYTA, INVEGA SUSTENNA, REXULTI, Qelbree, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
